Asthma drug trial halted early, but shows promise
NCT ID NCT06592768
First seen Oct 01, 2025 · Last updated May 17, 2026 · Updated 31 times
Summary
This study tested a single dose of briquilimab in 17 adults with mild-to-moderate allergic asthma to see if it could reduce allergic reactions and improve breathing. The trial was terminated early, so results are limited. The goal was to find a new way to control asthma symptoms by blocking certain immune cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC ASTHMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
McMaster University
Hamilton, Ontario, L8N 3Z5, Canada
-
University of Alberta
Edmonton, Alberta, T6G 2R3, Canada
-
University of British Columbia
Vancouver, British Columbia, V6T 1Z4, Canada
-
University of Calgary
Calgary, Alberta, T2N 1N4, Canada
-
University of Laval
Québec, Quebec, G1V 0A6, Canada
-
University of Saskatchewan
Saskatoon, Saskatchewan, S7N 5A2, Canada
Conditions
Explore the condition pages connected to this study.